Intravenous Magnesium Sulphate Versus in Wetting solution in Counteracting Epinephrine Cardiac Adverse Events: Prospective Randomized controlled Trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202105734020705

Enrollment

129

Registered

2021-05-31

Start date

2020-12-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

evaluate the efficacy of intravenous versus wetting solution MgSO4

Intravenous Magnesium Sulphate Versus in Wetting solution in Counteracting Epinephrine side effects

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients of both genders aged between 20 and 60 years. Classified by American society of anesthesiologists (ASA) I or II BMI 21-35 Kg/m2 who is preparing for abdominal liposuction procedure will be enrolled in our study.

Exclusion criteria

Exclusion criteria: Patients' refusal to participate liposuction for other body part body mass index =40 known renal or hepatic insufficiency, cardiac disorders known allergy to study drugs.

Design outcomes

Primary

Measure	Time frame
evaluate the efficacy of intravenous versus wetting solution MgSO4 in counteracting epinephrine induced cardiac adverse events (e.g. tachyarrhythmia, and hypertension) as primary outcome	—

Secondary

Measure	Time frame
evaluate the efficacy of intravenous versus wetting solution MgSO4on pain scores and total analgesic requirement as secondary outcome.	—

Countries

Egypt

Contacts

Public Contactrehab helal

Lecturer of Anaethesia and surgical intensive care and pain management

roro_helal85@yahoo.com+201092268262

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026